Moberg Pharma AB: Clinical Trials

5 completed. 5 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	5	Completed 5
Phase 2	1	Completed 1

Follow Moberg Pharma AB: new trials by email

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study of the Systemic Absorption of MOB015B MOB015B - Onychomycosis	Phase 1	Completed	Moberg Pharma AB	20	2017-12-16	2018-05-03
Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design MOB015B, 0.2% SLS, 0.9% Saline - Erythema	Phase 1	Completed	Moberg Pharma AB	45	2017-10-19	2024-04-17
Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design MOB015B, MOB015B vehicle, Negative irritant solution of 0.9% saline - Erythema	Phase 1	Completed	Moberg Pharma AB	250	2017-10-15	2024-04-17
Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind Study K201 - Atopic Dermatitis	Phase 1 / Phase 2	Completed	Moberg Pharma AB			2009-11-06
A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects Imiquimod (topical use) - Healthy	Phase 1	Completed	Moberg Pharma AB			2012-05-28

Conditions studied

Erythema (2)  ·  Dermatitis, Atopic (1)  ·  Onychomycosis (1)

Interventions

Imiquimod (1)  ·  K201 compound (1)  ·  Saline Solution (1)  ·  Sodium Chloride (1)  ·  long-chain-aldehyde dehydrogenase (1)

Countries

United States (3)  ·  Germany (2)

Top investigators

Jonathan S Dosik, MD (1)

Results publications

PMID 39158295